Amicus Therapeutics Prelim Results, Outlook Disappoint

 Full-Year 2021 Galafold® Revenue of ~$306M, Representing 17% YoY Growth

Expect Double-Digit Growth (15-20%) of 2022 Galafold Revenue with $350M-$365M in Global Sales

U.S. and EU Regulatory Reviews Underway for AT-GAA in Pompe Disease

AT-GAA Global Launch Preparations Accelerating

Cash Flow and Balance Sheet Sufficient to Achieve Self-Sustainability and Profitability by 2023

Amicus is focused on the following five key strategic priorities in 2022:

• Continued double-digit Galafold growth (15-20%) with revenue of $350M to $365M

• Secure FDA approval and positive CHMP opinion for AT-GAA

• Initiate successful, rapid launch in the U.S. for AT-GAA

• Advance best-in-class next generation genetic medicines and capabilities

• Maintain strong financial position on path to profitability
  

Mr. Crowley and Mr. Campbell will discuss the Amicus corporate objectives and key milestones in a presentation at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 3:45 p.m. ET. A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.

https://finance.yahoo.com/news/amicus-therapeutics-reports-preliminary-2021-120000501.html